{"id":5091,"date":"2012-04-22T09:00:00","date_gmt":"2012-04-22T09:00:00","guid":{"rendered":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-bij-klinische-test-van-aat\/"},"modified":"2024-09-23T11:22:45","modified_gmt":"2024-09-23T11:22:45","slug":"positieve-resultaten-bij-klinische-test-van-aat","status":"publish","type":"post","link":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-bij-klinische-test-van-aat\/","title":{"rendered":"Positieve resultaten bij klinische test van AAT"},"content":{"rendered":"Het Israelische bedrijf Kamada heeft een interim rapportage uitgebracht over een klinische trial met D1-AAT. Dit is een variant van het normaal in het lichaam voorkomende eiwit Alpha-1 Antitripsin, vaak afgekort tot AAT. AAT heeft een remmende werking op diverse acties van het immuunsysteem, met name in de longen maar ook in andere delen van het lichaam. Kamada rapporteert dat D1-AAT een stabiliserende werking lijkt te hebben op T1D en de manifestatie van de ziekte zelfs kan verminderen. Het bedrijf stelt nadrukkelijk dat de gegevens komen van een klein en nog kortdurend onderzoek en dus met voorzichtigheid moeten worden ge\u00efnterpreteerd.\n\n<a href=\"http:\/\/asweetlife.org\/a-sweet-life-staff\/in-the-news\/drugs-treatment\/kamada-announces-positive-preliminary-results-for-new-type-1-diabetes-therapy\/26504\/\">Lees verder (Engelstalig)<\/a>","protected":false,"raw":""},"excerpt":{"rendered":"<p>Het Israelische bedrijf Kamada heeft een interim rapportage uitgebracht over een klinische trial met D1-AAT. Dit is een variant van het normaal in het lichaam voorkomende eiwit Alpha-1 Antitripsin, vaak afgekort tot AAT. AAT heeft een remmende werking op diverse acties van het immuunsysteem, met name in de longen maar ook in andere delen van [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[184,195],"tags":[],"class_list":["post-5091","post","type-post","status-publish","format-standard","hentry","category-archief","category-voorkomen"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Positieve resultaten bij klinische test van AAT - Breakthrough T1D<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-bij-klinische-test-van-aat\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Positieve resultaten bij klinische test van AAT - Breakthrough T1D\" \/>\n<meta property=\"og:description\" content=\"Het Israelische bedrijf Kamada heeft een interim rapportage uitgebracht over een klinische trial met D1-AAT. Dit is een variant van het normaal in het lichaam voorkomende eiwit Alpha-1 Antitripsin, vaak afgekort tot AAT. AAT heeft een remmende werking op diverse acties van het immuunsysteem, met name in de longen maar ook in andere delen van [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-bij-klinische-test-van-aat\/\" \/>\n<meta property=\"og:site_name\" content=\"Breakthrough T1D\" \/>\n<meta property=\"article:published_time\" content=\"2012-04-22T09:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-23T11:22:45+00:00\" \/>\n<meta name=\"author\" content=\"ylt-admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschreven door\" \/>\n\t<meta name=\"twitter:data1\" content=\"ylt-admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Geschatte leestijd\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-bij-klinische-test-van-aat\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-bij-klinische-test-van-aat\/\"},\"author\":{\"name\":\"ylt-admin\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\"},\"headline\":\"Positieve resultaten bij klinische test van AAT\",\"datePublished\":\"2012-04-22T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-bij-klinische-test-van-aat\/\"},\"wordCount\":114,\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"articleSection\":[\"Archief\",\"Voorkomen\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-bij-klinische-test-van-aat\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-bij-klinische-test-van-aat\/\",\"name\":\"Positieve resultaten bij klinische test van AAT - Breakthrough T1D\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\"},\"datePublished\":\"2012-04-22T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-bij-klinische-test-van-aat\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-bij-klinische-test-van-aat\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-bij-klinische-test-van-aat\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/breakthrought1d.eu\/nl\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Positieve resultaten bij klinische test van AAT\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"name\":\"Breakthrough T1D\",\"description\":\"Wij zetten ons in voor een toekomst zonder T1D\",\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\",\"name\":\"Breakthrough T1D\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"contentUrl\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"width\":330,\"height\":141,\"caption\":\"Breakthrough T1D\"},\"image\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\",\"name\":\"ylt-admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"caption\":\"ylt-admin\"},\"sameAs\":[\"https:\/\/87.250.144.92\"],\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Positieve resultaten bij klinische test van AAT - Breakthrough T1D","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-bij-klinische-test-van-aat\/","og_locale":"nl_NL","og_type":"article","og_title":"Positieve resultaten bij klinische test van AAT - Breakthrough T1D","og_description":"Het Israelische bedrijf Kamada heeft een interim rapportage uitgebracht over een klinische trial met D1-AAT. Dit is een variant van het normaal in het lichaam voorkomende eiwit Alpha-1 Antitripsin, vaak afgekort tot AAT. AAT heeft een remmende werking op diverse acties van het immuunsysteem, met name in de longen maar ook in andere delen van [&hellip;]","og_url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-bij-klinische-test-van-aat\/","og_site_name":"Breakthrough T1D","article_published_time":"2012-04-22T09:00:00+00:00","article_modified_time":"2024-09-23T11:22:45+00:00","author":"ylt-admin","twitter_card":"summary_large_image","twitter_misc":{"Geschreven door":"ylt-admin","Geschatte leestijd":"1 minuut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-bij-klinische-test-van-aat\/#article","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-bij-klinische-test-van-aat\/"},"author":{"name":"ylt-admin","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6"},"headline":"Positieve resultaten bij klinische test van AAT","datePublished":"2012-04-22T09:00:00+00:00","dateModified":"2024-09-23T11:22:45+00:00","mainEntityOfPage":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-bij-klinische-test-van-aat\/"},"wordCount":114,"publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"articleSection":["Archief","Voorkomen"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-bij-klinische-test-van-aat\/","url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-bij-klinische-test-van-aat\/","name":"Positieve resultaten bij klinische test van AAT - Breakthrough T1D","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#website"},"datePublished":"2012-04-22T09:00:00+00:00","dateModified":"2024-09-23T11:22:45+00:00","breadcrumb":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-bij-klinische-test-van-aat\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-bij-klinische-test-van-aat\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-bij-klinische-test-van-aat\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/breakthrought1d.eu\/nl\/"},{"@type":"ListItem","position":2,"name":"Positieve resultaten bij klinische test van AAT"}]},{"@type":"WebSite","@id":"https:\/\/breakthrought1d.eu\/nl\/#website","url":"https:\/\/breakthrought1d.eu\/nl\/","name":"Breakthrough T1D","description":"Wij zetten ons in voor een toekomst zonder T1D","publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/breakthrought1d.eu\/nl\/#organization","name":"Breakthrough T1D","url":"https:\/\/breakthrought1d.eu\/nl\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/","url":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","contentUrl":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","width":330,"height":141,"caption":"Breakthrough T1D"},"image":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6","name":"ylt-admin","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","caption":"ylt-admin"},"sameAs":["https:\/\/87.250.144.92"],"url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/"}]}},"_links":{"self":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5091","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/comments?post=5091"}],"version-history":[{"count":1,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5091\/revisions"}],"predecessor-version":[{"id":7307,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5091\/revisions\/7307"}],"wp:attachment":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/media?parent=5091"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/categories?post=5091"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/tags?post=5091"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}